心肌梗死后损伤最小化:聚焦细胞外囊泡
急性心肌梗死后死亡率仍高,尤其左室射血分数(LVEF)<30%者,亟需再通外的有效心肌保护策略。传统细胞疗法效果不明确,细胞外囊泡(EVs)作为携带非编码RNA等生物分子的旁分泌载体,具稳定性、易储存和低免疫原性等优势。本综述探讨基于EVs的治疗转化潜力,重点介绍大动物研究结果及早期临床试验概况。
要点
- LVEF<30%的心梗患者死亡率仍高,需再通外的辅助心肌保护策略。
- EVs携带非编码RNA等,以旁分泌方式影响邻近和远端细胞功能。
- 同种异体间充质/心脏基质祖细胞来源EVs在临床前显示安全且可能有效。
核心结论
- EVs作为新型心脏活性生物制剂,在心肌梗死后损伤最小化方面具转化潜力。
研究设计与样本
- 综述,聚焦EVs治疗转化潜力,重点总结大动物研究并概述早期临床试验。
主要发现
- LVEF<30%的急性心梗患者死亡率仍高,传统细胞疗法成功不明确。
- EVs具稳定性、易储存(可现货供应)和低免疫原性等临床优势。
- 间充质和/或心脏基质祖细胞来源的同种异体EVs在临床前显示安全且可能有效。
临床怎么用
- EVs有望作为再通辅助的心肌保护策略,但当前证据主要来自临床前及早期试验。
局限性
- 证据主要来自临床前大动物研究,早期临床试验尚在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF <30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of non-coding RNAs and other essential biomolecules, influence neighbouring and remote cell function in a paracrine manner. Compared to cell therapy, EVs possess several clinically advantageous traits, including stability, ease of storage (enabling off-the-shelf clinical readiness), and decreased immunogenicity. Allogeneic EVs from mesenchymal and/or cardiac stromal progenitor cells demonstrate safety and potential efficacy in preclinical settings. This review delves into the translational potential of EV-based therapeutic approaches, specifically highlighting findings from large-animal studies, and offers a synopsis of ongoing early-stage clinical trials in this domain.
引用
- Barile, Marbán. Injury minimization after myocardial infarction: focus on extracellular vesicles. Eur Heart J. 2024. PMID: 38366191. doi:10.1093/eurheartj/ehae089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。